secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evofem Biosciences, Inc. (EVFM)
CIK:        0001618835
Form:       8-K
Filed at:   2023-11-14T23:59:59+00:00
Accession:  0001493152-23-040762
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evofem Q3 revenue $5.1M (-20% YoY); op loss narrows 81%; debt restructured; generic threat removed
--------------------------------------------------------------------------------

- Net product sales $5.1M in Q3 vs $6.4M YoY; selling and marketing expenses cut 75%.
- Net income $66M ($15.34 basic) from debt extinguishment gain; operating loss improved to $3.6M from $18.7M.
- Fourth Amendment to $25M notes: waived default, removed revenue covenant; repurchase possible for as low as $14M.
- Generic drug maker withdrew ANDA; will not seek FDA approval until Evofem Phexxi patents expire (2033).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1618835/000149315223040762/0001493152-23-040762-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1618835/000149315223040762/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-040762

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer